EP Patent

EP2924034A1 — Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor

Assigned to Merck Canada Inc · Expires 2015-09-30 · 11y expired

What this patent protects

The invention relates to a pharmaceutical composition comprising an effective amount of the compound: or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and further comprising an effective amount of an anti-HIV agent. The invention furth…

USPTO Abstract

The invention relates to a pharmaceutical composition comprising an effective amount of the compound: or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and further comprising an effective amount of an anti-HIV agent. The invention further relates to use of said pharmaceutical composition for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP2924034A1
Jurisdiction
EP
Classification
—
Expires
2015-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Merck Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.